Results 211 to 220 of about 240,151 (268)

Limited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes. [PDF]

Int J Mol Sci
Ratka Z, Gamian A, Woźniak M.
europepmc   +1 more source

CEBPG‐Mediated Palmitic Acid Adaptation of Cancer‐Associated Fibroblasts Drives Metastasis of Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
This study reveals a metabolic signaling axis in the OSCC microenvironment where palmitic acid (PA) drives the activation of CAFs. PA uptake triggers CEBPG‐dependent epigenetic remodeling to upregulate ERN1 and TMBIM6, thereby mitigating ER stress. This adaptive program sustains CAF survival and the pro‐metastatic phenotype, establishing this pathway ...
Yiling Duan, Yitong Li, Yufei Wu, Xiao Yang, Rui Li, Hui Zhao, Zhengjun Shang   +6 more
wiley   +1 more source

Progressive Conduction Disease on Serial ECGs Revealing Immune Checkpoint Inhibitor-Associated Myocarditis and Myositis. [PDF]

JACC Case Rep
Nelson QM, Greenberg J, Abdelkarim I, Lee J, Puckett CM.   +4 more
europepmc   +1 more source

Immune Checkpoint Inhibitor-Induced Endocrine Dysfunction: Early Detection of Symptoms and Timely Intervention. [PDF]

Clin Case Rep
Obaed NG, Fofana K, Matarneh A, Sardar S, Trivedi N, Ghahramani N.   +5 more
europepmc   +1 more source

Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors. [PDF]

Clin Cancer Res
Mechahougui H, Royston L, Vieira Gomes C, Kaiser L, Koessler T, Olivier T, Mach N, Labidi-Galy SI, Parikh K, Addeo A.   +9 more
europepmc   +1 more source

Prediction of Patients' Response to Immune Checkpoint Inhibitors Using Fluorescence Lifetime Imaging of Lymphocytes. [PDF]

Biomedicines
Yuzhakova DV, Kononova AI, Izosimova AV, Sazhina MM, Dudenkova VV, Elagin VV, Bureev PA, Kuzmin DA, Gavrina AI, Shumskaya IS, Gamaynov SV, Shirmanova MV.   +11 more
europepmc   +1 more source

Dosing, duration, and timing controversies in determining immune checkpoint inhibitor dosing regimens. [PDF]

NPJ Precis Oncol
Buma AIG, Bol KF, van Erp NP, Aarntzen EHJG, Piet B, van den Heuvel MM, Ter Heine R.   +6 more
europepmc   +1 more source

Genomic landscape of immune checkpoint inhibitor-induced aplastic anemia: a case report. [PDF]

Front Oncol
Takahashi N, Harano K, Funasaka C, Nakajima H, Kondoh C, Matsubara N, Hosono A, Naito Y, Nagamine M, Tanabe H, Fujisawa T, Nakamura Y, Bando H, Yoshino T, Yuda J, Mukohara T.   +15 more
europepmc   +1 more source

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients.

JAMA Netw Open
Wan G, Nguyen N, Lu C, Khattab S, Yan B, Amadife M, Leung BW, Chen W, Rajeh A, Tang K, Thang C, Boland G, Reynolds KL, Yu KH, Gusev A, LeBoeuf NR, Kwatra SG, Semenov YR.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immune Checkpoint Inhibitors in the Aged

Current Oncology Reports, 2021
Large phase III trials have established the benefit of checkpoint blockade across multiple tumor types, but patient representation is limited in some subgroups including the aged population. There are several changes in the immune system that occur with age (termed immunosenescence) that could potentially limit efficacy in aged populations.Despite the ...
James Isaacs, Scott Antonia, Jeffrey Clarke   +2 more
openaire   +2 more sources